Dr Gerard Walls speaks to ecancer about the brief report from the CONVERT trial. The study investigated the long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small-cell lung cancer. This updated analysis described the 6.5-year outcomes of these regimes delivered with conformal techniques.

The results from this trial did not demonstrate the superiority of once-daily radiotherapy and this regime had a slightly worse toxicity profile after 80 months of follow-up. Therefore, 45 Gy twice daily radiotherapy remains the standard of care in limited-stage small-cell lung cancer.